1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunity Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immune Checkpoint Inhibitor
1.2.3 Cytokine Immunotherapy
1.2.4 Cancer Vaccine
1.2.5 Car-t Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Tumor Immunity Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunity Therapy Market Perspective (2018-2029)
2.2 Tumor Immunity Therapy Growth Trends by Region
2.2.1 Global Tumor Immunity Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor Immunity Therapy Historic Market Size by Region (2018-2023)
2.2.3 Tumor Immunity Therapy Forecasted Market Size by Region (2024-2029)
2.3 Tumor Immunity Therapy Market Dynamics
2.3.1 Tumor Immunity Therapy Industry Trends
2.3.2 Tumor Immunity Therapy Market Drivers
2.3.3 Tumor Immunity Therapy Market Challenges
2.3.4 Tumor Immunity Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunity Therapy Players by Revenue
3.1.1 Global Top Tumor Immunity Therapy Players by Revenue (2018-2023)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunity Therapy Revenue
3.4 Global Tumor Immunity Therapy Market Concentration Ratio
3.4.1 Global Tumor Immunity Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunity Therapy Revenue in 2022
3.5 Tumor Immunity Therapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunity Therapy Product Solution and Service
3.7 Date of Enter into Tumor Immunity Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunity Therapy Breakdown Data by Type
4.1 Global Tumor Immunity Therapy Historic Market Size by Type (2018-2023)
4.2 Global Tumor Immunity Therapy Forecasted Market Size by Type (2024-2029)
5 Tumor Immunity Therapy Breakdown Data by Application
5.1 Global Tumor Immunity Therapy Historic Market Size by Application (2018-2023)
5.2 Global Tumor Immunity Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tumor Immunity Therapy Market Size (2018-2029)
6.2 North America Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tumor Immunity Therapy Market Size by Country (2018-2023)
6.4 North America Tumor Immunity Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immunity Therapy Market Size (2018-2029)
7.2 Europe Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tumor Immunity Therapy Market Size by Country (2018-2023)
7.4 Europe Tumor Immunity Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunity Therapy Market Size (2018-2029)
8.2 Asia-Pacific Tumor Immunity Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor Immunity Therapy Market Size (2018-2029)
9.2 Latin America Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tumor Immunity Therapy Market Size by Country (2018-2023)
9.4 Latin America Tumor Immunity Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunity Therapy Market Size (2018-2029)
10.2 Middle East & Africa Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Introduction
11.1.4 Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Detail
11.2.2 Merck & Co., Inc. Business Overview
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Introduction
11.2.4 Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.2.5 Merck & Co., Inc. Recent Development
11.3 Roche AG
11.3.1 Roche AG Company Detail
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Tumor Immunity Therapy Introduction
11.3.4 Roche AG Revenue in Tumor Immunity Therapy Business (2018-2023)
11.3.5 Roche AG Recent Development
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Detail
11.4.2 AstraZeneca, Plc Business Overview
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Introduction
11.4.4 AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2018-2023)
11.4.5 AstraZeneca, Plc Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Detail
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Tumor Immunity Therapy Introduction
11.5.4 Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.5.5 Sanofi S.A. Recent Development
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Detail
11.6.2 Dendreon Pharmaceuticals Business Overview
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Introduction
11.6.4 Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2018-2023)
11.6.5 Dendreon Pharmaceuticals Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Tumor Immunity Therapy Introduction
11.7.4 Novartis Revenue in Tumor Immunity Therapy Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Detail
11.8.2 Gilead Sciences Inc. Business Overview
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Introduction
11.8.4 Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.8.5 Gilead Sciences Inc. Recent Development
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Detail
11.9.2 IMVAQ Therapeutics Business Overview
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Introduction
11.9.4 IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023)
11.9.5 IMVAQ Therapeutics Recent Development
11.10 Arch Oncology
11.10.1 Arch Oncology Company Detail
11.10.2 Arch Oncology Business Overview
11.10.3 Arch Oncology Tumor Immunity Therapy Introduction
11.10.4 Arch Oncology Revenue in Tumor Immunity Therapy Business (2018-2023)
11.10.5 Arch Oncology Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Detail
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics Tumor Immunity Therapy Introduction
11.11.4 Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023)
11.11.5 Juno Therapeutics Recent Development
11.12 Refuge
11.12.1 Refuge Company Detail
11.12.2 Refuge Business Overview
11.12.3 Refuge Tumor Immunity Therapy Introduction
11.12.4 Refuge Revenue in Tumor Immunity Therapy Business (2018-2023)
11.12.5 Refuge Recent Development
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Detail
11.13.2 Lepu Biopharma Business Overview
11.13.3 Lepu Biopharma Tumor Immunity Therapy Introduction
11.13.4 Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2018-2023)
11.13.5 Lepu Biopharma Recent Development
11.14 Genoimmune
11.14.1 Genoimmune Company Detail
11.14.2 Genoimmune Business Overview
11.14.3 Genoimmune Tumor Immunity Therapy Introduction
11.14.4 Genoimmune Revenue in Tumor Immunity Therapy Business (2018-2023)
11.14.5 Genoimmune Recent Development
11.15 TCR Cure
11.15.1 TCR Cure Company Detail
11.15.2 TCR Cure Business Overview
11.15.3 TCR Cure Tumor Immunity Therapy Introduction
11.15.4 TCR Cure Revenue in Tumor Immunity Therapy Business (2018-2023)
11.15.5 TCR Cure Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
